To the Editor The recent retrospective study by Hernandez et al1 reported that while dabigatran was associated with a lower rate of intracranial hemorrhage, the rate of major and gastrointestinal bleeding was higher relative to warfarin users in a Medicare cohort of patients with atrial fibrillation. To further substantiate these results, there are several aspects of this study that merit clarification.
Miyares MA. One-Year Risk of Bleeding With Dabigatran in Patients With Atrial FibrillationPlacing Real-World Results Into Perspective. JAMA Intern Med. 2015;175(7):1242-1243. doi:10.1001/jamainternmed.2015.1271